Back to Search
Start Over
Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
- Source :
- Conget, Ignacio Mauricio, Dídac Ortega, Rafael Detournay, Bruno Muros, Teresa De la Cuesta, Carmen Mangas Cruz, Miguel Ángel Hernández Herrero, Cristina De Castro Hernández, Paloma Gómez Peralta, Fernando Miralles García, José Manuel Martínez, Encarna Cuatrecasas, Guillem Aguilera, Eva Giménez, Margarita Vinagre, Irene Anglada, Jordi Pérez Maraver, Manuel Manzanares, Jose María Fernández Catalina, Pablo Bellido Guerrero, Diego Soto González, Alfonso Casanueva, Felipe Masmiquel, Lluís Gómez, Luis Alberto García, Honorato Arguelles, Iñaqui Garcia Puig, Juan Brito Sanfiel, Miguel Ángel Escalada, Francisco Javier Gaztambide, Sonia Hernández Mijares, Antonio Ampudia Blasco, Francisco Javier Tréscoli, Carlos Merino-Torres, Juan Francisco De Teresa Parreño, Luis 2016 Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain Bmj Open 6 e010197, RODERIC. Repositorio Institucional de la Universitat de Valéncia, instname, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona
- Publication Year :
- 2016
-
Abstract
- Ajuda rebuda: GlaxoSmithKline Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design. Cross-sectional observational study. Setting. Spanish specialist outpatient clinics.Participants 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures Sociodemographic and DM2-related clinical data, including treatment at and after GLP-1Ra initiation and comorbidities, were collected. Results Evaluable patients (n=403; 50.9% female) were included (July 2013 to March 2014) at 24 centres by 53 specialists (47 endocrinology, 6 internal medicine), with the following profile (value±SD): age (58.3±10.4 years), diabetes duration (9.9±7 years), body mass index (BMI; 36.2±5.5) and glycated haemoglobin (HbA1c; 8.4±1.4%); 14% had HbA1c≤7%. Previous antidiabetic treatment: 53.8% only oral antidiabetic drugs (OADs), 5.2% insulin and 40% insulin and OAD; of those receiving OAD, 35% single drug, 38.2% 2 drugs and 24% 3 drugs. Concomitant to GLP-1Ra, 55.3% were only on OAD, 36.2% on insulin and OAD, and 7.2% only on insulin. Of those receiving OAD, the GLP-1Ra was mainly associated with 1 drug (65%) or 2 drugs (31.8%). GLP-1Ra are frequently added to existing antidiabetic drugs, with dipeptidyl peptidase-4 inhibitors being the OAD most frequently switched (45% receiving 1 before starting GLP-1Ra, only 2.7% receiving it concomitantly).Conclusions In Spain, GLP-1Ra therapy is usually started in combination with OADs or OADs and insulin. These drugs are used in relatively young patients often not reaching therapeutic goals with other treatment combinations, roughly a decade after diagnosis and with a relatively high BMI. The latter could be explained by Spanish regional payers limiting reimbursed prescription to patients with a minimum BMI threshold (>30 in most regions, >35 in some).
- Subjects :
- medicine.medical_specialty
DM2
Cross-sectional study
medicine.medical_treatment
030209 endocrinology & metabolism
03 medical and health sciences
0302 clinical medicine
Insulina
Internal medicine
medicine
Outpatient clinic
030212 general & internal medicine
Medical prescription
Glucagon-like peptide 1 receptor
Diabetis
business.industry
Insulin
Diabetis mellitus tipus 2
Type 2 Diabetes Mellitus
General Medicine
Diabetes mellitus tipo 2
Endocrinology
Concomitant
Malalties d'origen nutricional
business
Body mass index
Subjects
Details
- Database :
- OpenAIRE
- Journal :
- Conget, Ignacio Mauricio, Dídac Ortega, Rafael Detournay, Bruno Muros, Teresa De la Cuesta, Carmen Mangas Cruz, Miguel Ángel Hernández Herrero, Cristina De Castro Hernández, Paloma Gómez Peralta, Fernando Miralles García, José Manuel Martínez, Encarna Cuatrecasas, Guillem Aguilera, Eva Giménez, Margarita Vinagre, Irene Anglada, Jordi Pérez Maraver, Manuel Manzanares, Jose María Fernández Catalina, Pablo Bellido Guerrero, Diego Soto González, Alfonso Casanueva, Felipe Masmiquel, Lluís Gómez, Luis Alberto García, Honorato Arguelles, Iñaqui Garcia Puig, Juan Brito Sanfiel, Miguel Ángel Escalada, Francisco Javier Gaztambide, Sonia Hernández Mijares, Antonio Ampudia Blasco, Francisco Javier Tréscoli, Carlos Merino-Torres, Juan Francisco De Teresa Parreño, Luis 2016 Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain Bmj Open 6 e010197, RODERIC. Repositorio Institucional de la Universitat de Valéncia, instname, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona
- Accession number :
- edsair.doi.dedup.....ec99cb3b5d9fec699ff146cf331f5137